Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan J Garber

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Diabetes Care|April 29, 2011
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerabilityAlan J Garber
Expert Opinion on Investigational Drugs|November 25, 2011
Novel GLP-1 receptor agonists for diabetesAlan J Garber
Journal of Diabetes|November 15, 2014
Biosimilar products are not bioidenticalAlan J Garber
The American Journal of Medicine|May 21, 2005
Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. IntroductionAlan J Garber
The American Journal of Managed Care|September 3, 2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care settingAlan J Garber
Lancet (London, England)|June 19, 2012
Hypoglycaemia: a therapeutic concern in type 2 diabetesAlan J Garber
The Journal of Family Practice|October 31, 2008
An overview of incretin clinical trialsAlan J Garber, Stephen J Spann
Endocrinology and Metabolism Clinics of North America|March 4, 2014
Metabolic syndromeSusan L Samson, Alan J Garber
Best Practice & Research. Clinical Endocrinology & Metabolism|July 20, 2016
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agentsSusan L Samson, Alan J Garber
Diabetes Care|March 29, 2005
Point: Inpatient glucose management: the emperor finally has clothesMichael Bryer-Ash, Alan J Garber
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Diabetes Care|April 29, 2011
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerabilityAlan J Garber
Expert Opinion on Investigational Drugs|November 25, 2011
Novel GLP-1 receptor agonists for diabetesAlan J Garber
Journal of Diabetes|November 15, 2014
Biosimilar products are not bioidenticalAlan J Garber
The American Journal of Medicine|May 21, 2005
Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. IntroductionAlan J Garber
The American Journal of Managed Care|September 3, 2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care settingAlan J Garber
Lancet (London, England)|June 19, 2012
Hypoglycaemia: a therapeutic concern in type 2 diabetesAlan J Garber
The Journal of Family Practice|October 31, 2008
An overview of incretin clinical trialsAlan J Garber, Stephen J Spann
Endocrinology and Metabolism Clinics of North America|March 4, 2014
Metabolic syndromeSusan L Samson, Alan J Garber
Best Practice & Research. Clinical Endocrinology & Metabolism|July 20, 2016
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agentsSusan L Samson, Alan J Garber
Diabetes Care|March 29, 2005
Point: Inpatient glucose management: the emperor finally has clothesMichael Bryer-Ash, Alan J Garber
Pageof 10